Anika Therapeutics, Inc. (ANIK)

US — Healthcare Sector
Peers: AXGN  OFIX  SRDX  FNA  AORT  SGHT  AVNS  KIDS  NPCE  CVRX  OSA  HSKA 

Automate Your Wheel Strategy on ANIK

With Tiblio's Option Bot, you can configure your own wheel strategy including ANIK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANIK
  • Rev/Share 7.3828
  • Book/Share 10.3796
  • PB 1.0848
  • Debt/Equity 0.1714
  • CurrentRatio 5.7264
  • ROIC -0.0947

 

  • MktCap 161484164.0
  • FreeCF/Share -0.2344
  • PFCF -48.1898
  • PE -2.837
  • Debt/Assets 0.1335
  • DivYield 0
  • ROE -0.3277

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ANIK B. Riley Securities -- Buy -- $21 April 17, 2025

News

Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript
ANIK
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Anderson Schock - B. Riley Securities Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company.

Read More
image for news Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
ANIK
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.31 per share a year ago.

Read More
image for news Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Anika Reports First Quarter 2025 Financial Results
ANIK
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral

First Quarter 2025 Commercial Channel revenue up 18% Integrity ™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025.

Read More
image for news Anika Reports First Quarter 2025 Financial Results
Is the Options Market Predicting a Spike in Anika Therapeutics Stock?
ANIK
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral

Investors need to pay close attention to ANIK stock based on the movements in the options market lately.

Read More
image for news Is the Options Market Predicting a Spike in Anika Therapeutics Stock?
Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025
ANIK
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

Read More
image for news Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025
ANIK
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Read More
image for news Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025
Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference
ANIK
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor meetings throughout the event.

Read More
image for news Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference

About Anika Therapeutics, Inc. (ANIK)

  • IPO Date 1993-05-03
  • Website https://www.anikatherapeutics.com
  • Industry Medical - Devices
  • CEO Dr. Cheryl Renee Blanchard Ph.D.
  • Employees 288

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.